Lipov E, Candido K. Efficacy and safety of stellate ganglion block in chronic ulcerative colitis. World J Gastroenterol 2017; 23(17): 3193-3194 [PMID: 28533676 DOI: 10.3748/wjg.v23.i17.3193]
Corresponding Author of This Article
Eugene Lipov, MD, Department of Anesthesiology, Advocate Illinois Masonic Medical Center, 3000 N Halsted St 700, Chicago, IL 60657, United States. elipovmd@aol.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letters To The Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. May 7, 2017; 23(17): 3193-3194 Published online May 7, 2017. doi: 10.3748/wjg.v23.i17.3193
Efficacy and safety of stellate ganglion block in chronic ulcerative colitis
Eugene Lipov, Ken Candido
Eugene Lipov, Ken Candido, Department of Anesthesiology, Advocate Illinois Masonic Medical Center, Chicago, IL 60657, United States
Author contributions: Lipov E wrote the paper, analyzed data; Candido K revised the paper.
Conflict-of-interest statement: None to declare.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Eugene Lipov, MD, Department of Anesthesiology, Advocate Illinois Masonic Medical Center, 3000 N Halsted St 700, Chicago, IL 60657, United States. elipovmd@aol.com
Telephone: +1-312-6180829 Fax: +1-312-6444343
Received: January 27, 2017 Peer-review started: February 4, 2017 First decision: March 16, 2017 Revised: April 10, 2017 Accepted: April 12, 2017 Article in press: April 12, 2017 Published online: May 7, 2017 Processing time: 99 Days and 18.7 Hours
Abstract
Sympathetic system modulation by stellate ganglion blockade may modulate immune dysfunction and significantly improve symptoms of chronic ulcerative colitis.
Core tip: Utility of stellate ganglion block (SGB) seems to be expanding rapidly at this time, finding of its effect on ulcerative colitis is novel. Dr. Zhao’s explanation of the clinical observation seems to be increased blood flow. This theory may be refined based on prior reports of SGB having a significant immunologic effects. Since, ulcerative colitis is considered to be an auto immune disease, modulation immune system by SGB seems a more likely explanation. Further research of modulating immunologic system by utilizing sympathetic blocks may be spurred on by Dr. Zhao’s observation.
